WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Astrazeneca revenue was $58.13B for the trailing 12 months ending Sep 30, 2025, with 44.9% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $15.2B, up 5.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AZN annual revenue was $54.1B, with 18% growth year-over-year.

AZN past revenue growth

How has AZN's revenue growth performed historically?

Company
13.52%
Industry
18.32%
Market
21.98%
AZN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AZN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AZN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AZN revenue history

Current Revenue
$58.1B
Current Earnings
$9.4B
Current Profit Margin
16.2%
AZN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

Be the first to know when AZN announces revenue.

AZN Revenue History By Year

AZN Yearly RevenueAZN RevenueAZN ChangeAZN Revenue Growth
2024-12-31$54.07B$8.26B+18.03%
2023-12-31$45.81B$1.46B+3.29%
2022-12-31$44.35B$6.93B+18.53%
2021-12-31$37.42B$10.80B+40.58%
2020-12-31$26.62B$2.23B+9.16%
2019-12-31$24.38B$2.29B+10.38%
2018-12-31$22.09B-$375.00M-1.67%
2017-12-31$22.47B-$537.00M-2.33%
2016-12-31$23.00B-$1.71B-6.90%
2015-12-31$24.71B-$1.84B-6.93%
2014-12-31$26.55B$741.00M+2.87%
2013-12-31$25.81B-$2.17B-7.75%
2012-12-31$27.97B-$5.62B-16.72%
2011-12-31$33.59B$322.00M+0.97%
2010-12-31$33.27B$465.00M+1.42%
2009-12-31$32.80B$1.20B+3.81%
2008-12-31$31.60B$2.04B+6.91%
2007-12-31$29.56B$3.08B+11.65%
2006-12-31$26.48B$2.53B+10.54%
2005-12-31$23.95B$2.52B+11.78%
2004-12-31$21.43B$2.58B+13.67%
2003-12-31$18.85B$1.01B+5.65%
2002-12-31$17.84BN/AN/A
2001-12-31N/AN/AN/A
2000-12-31N/AN/AN/A

1 of 2

Astrazeneca Revenue FAQ

What was AZN's revenue last quarter?

On Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q3 2025 revenue of $15.19 billion up 11.99% year over year. In the same quarter last year, Astrazeneca's revenue was $13.57 billion.

What was Astrazeneca's revenue in 2024?

Astrazeneca's annual revenue for the twelve months ending Dec 31, 2024 was $54.07 billion, a 18.03% increase year over year.

How much does Astrazeneca make in a day?

Based on Astrazeneca annual revenue for the past five years, AZN makes an average of $114,120,000.00 per day.

What was Astrazeneca's annual revenue growth in the past year?

As of Q4 2025, Astrazeneca's revenue has grown 13.52% year over year. This is 4.8 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 18.32%. Astrazeneca's revenue in the past year totaled $58.13 billion.

How much does Astrazeneca make in a year?

Astrazeneca's revenue by year for the past five years is:
  • Astrazeneca's revenue for the twelve months ending Dec 31, 2024 was $54.07 billion, a 18.03% increase year over year.
  • Astrazeneca's annual revenue for Dec 31, 2023 was $45.81 billion, a 3.29% increase from 2022.
  • Astrazeneca's annual revenue for 2022 was $44.35 billion, a 18.53% increase from 2021.
  • Astrazeneca's annual revenue for 2021 was $37.42 billion, a 40.58% increase from 2020.
  • Astrazeneca's annual revenue for 2020 was $26.62 billion, a 9.16% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.